Comorbidity of neurological manifestations in COVID-19

June 18, 2025
525
УДК:  616.98:578.834COVID-19]-06-092.11:616.8-008.6
Resume

Comorbid conditions in COVID-19 can not only increase the severity of the underlying disease, but also worsen the quality of life in these patients. In Ukraine, the largest share of comorbid conditions are pathologies of the circulatory system, respiratory and digestive systems, diseases of the musculoskeletal and endocrine systems. The risk factor for comorbid conditions is primarily the patient’s age. One of the important aspects of the formation of comorbidity is psychosocial disorders, which cause a significant adverse effect on the risk of development, course and prognosis of the underlying disease.

References

  • 1. Guan W.J., Ni Z.Y., Hu Y. et al. (2020) Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 382: 1708–1720.
  • 2. Huang C., Wang Y., Li X. et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395: 497–506.
  • 3. Deng S.-Q., Peng H.-J. (2020) Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J. Clin. Med., 9(2): 575.
  • 4. Peng Y. D., Meng K., Guan H.Q. et al. (2020) Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chinese J. Cardiol., 48(6): 450–455.
  • 5. Zhou F., Yu T., Du R. et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395: 1054–1062.
  • 6. Campbell-Scherer D. (2010) Multimorbidity: a challenge for evidencebased medicine. Evid. Based Med., 15: 165–166. doi: 10.1136/ebm1154.
  • 7. Caughey G.E., Ramsay E.N., Vitry A.I. et al. (2010) Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. Community Health, 64: 1036–1042.
  • 8. Marrie R.A., Rudick R., Horwitz R. et al. (2010) Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurol., 74: 1041–1047. doi: 10.1212/ WNL.0b013e3181d6b125.